Its overexpression is closely associated with clinical malignant phenotypes, suggesting that SNHG14 not only plays a crucial role in the initiation and progression of thyroid cancer but may also serve as a potential molecular target and prognostic biomarker. This evidence concerns the gene SNHG14 and thyroid cancer.